DaVita stock slides 2.25% and underperforms competitors
Updated
Updated · MarketWatch · May 1
DaVita stock slides 2.25% and underperforms competitors
11 articles · Updated · MarketWatch · May 1
Shares closed at $151.65 on Friday, lagging UnitedHealth, Quest Diagnostics and Icon in a mixed US market session as the S&P 500 rose 0.29% and the Dow fell 0.31%.
The decline ended a three-day winning streak and left the kidney-care provider 4.87% below its 52-week high of $159.42 reached on 2 March.
Trading volume was 579,373 shares, about 195,080 below DaVita's 50-day average of 774,453, suggesting lighter-than-usual activity during the pullback.
Why do valuation models suggest DaVita is a steal while analysts remain cautious?
As new drugs reshape kidney care, can DaVita's business model survive future medical breakthroughs?